Furthr VC

Furthr VC, formerly DBIC Ventures, is a Dublin-based venture firm focused on backing scalable B2B software and digital health enterprises in Ireland. The rebrand to Furthr reflects the firm’s evolution beyond its earlier Dublin Business Innovation Centre roots into a more conventional venture vehicle, while retaining the deep ties to the Irish entrepreneurial community that the firm has built over decades.

The thesis is centered on B2B software with strong commercial fundamentals, with healthcare software and digital health as one of several priority verticals. In practice, this includes clinical operations and patient engagement tools, AI applications in healthcare workflows, life sciences software, and adjacent enterprise SaaS categories where the firm can underwrite a credible path to commercial scale. The firm tends to favor companies that have moved past pure prototype and are working with real customers, rather than purely research-stage bets.

Investments are typically Seed and Series A with checks of roughly two hundred fifty thousand to one million dollars. Geographic focus is Ireland with selective activity in the broader UK and European markets. Furthr leads or co-leads at smaller stages and participates alongside larger UK and European investors as companies progress, often working with Enterprise Ireland co-investment programs.

The team is built around investing partners and principals with backgrounds across Irish entrepreneurship, enterprise software, and venture capital. Founders should expect engagement that is rooted in the Irish ecosystem and practical about the realities of growing an Irish business, including expansion to the United States and the United Kingdom and the recruiting and operational challenges that come with it.

The practical value of Furthr is a substantive Irish lead with strong relationships across the local ecosystem and a credible track record of helping companies progress to follow-on rounds. Portfolio companies benefit from introductions to Irish customers, follow-on investors in the UK and US, and access to Enterprise Ireland matched funding when relevant. The trade-off is the same as most regional seed funds: check sizes are modest, and most portfolio companies will need to add larger investors to fund Series A and beyond. The fit is strongest for Irish B2B SaaS and digital health founders who want a meaningful local lead and are realistic about the funding stack required to scale, and weaker for medtech or biotech companies whose funding profile is not well served by software-oriented seed economics.